Neonatal Jaundice Calculator
Phototherapy & Exchange Transfusion Thresholds for Newborns ≥35 Weeks
Patient Details
Phototherapy Threshold Quick Reference (AAP 2022)
| Age | ≥38 Wk, Low Risk (mg/dL) | 35–37 Wk / Any Risk Factor (mg/dL) |
|---|---|---|
| 24 hours | 8.0 | 6.0 |
| 48 hours | 13.0 | 11.0 |
| 72 hours | 16.0 | 13.0 |
| 96 hours (≥4 days) | 18.0 | 15.0 |
| ≥5 days | 18.0 | 15.0 |
Understanding Neonatal Jaundice (Hyperbilirubinemia)
Neonatal jaundice is one of the most common clinical conditions in newborns, affecting approximately 60% of term and 80% of preterm infants in the first week of life. While most cases are physiological and self-limiting, elevated bilirubin beyond certain thresholds carries a risk of neurotoxicity — specifically bilirubin-induced neurological dysfunction (BIND), which in its most severe form causes kernicterus, a permanent and devastating neurological injury.
Total serum bilirubin (TSB) or transcutaneous bilirubin (TcB) is the primary measurement used to monitor and guide treatment decisions. The AAP 2022 revised guidelines fundamentally changed management by lowering phototherapy thresholds (especially for late preterm infants), mandating universal predischarge bilirubin screening, and stratifying recommendations by neurotoxicity risk factors.
Physiological vs. Pathological Jaundice
Physiological jaundice appears after 24 hours of age, peaks between days 3–5 in term infants (days 5–7 in preterm), and resolves by 1–2 weeks. It is caused by the normal neonatal breakdown of fetal haemoglobin combined with temporary hepatic immaturity. No treatment is typically required unless thresholds are crossed.
Pathological jaundice is defined by its timing (onset within 24 hours), rate of rise (>5 mg/dL/24h), severity (crossing phototherapy threshold), or prolonged duration (>2 weeks term, >3 weeks preterm). Causes include ABO/Rh isoimmune haemolysis, G6PD deficiency, sepsis, hypothyroidism, biliary atresia, and metabolic disorders. All jaundice in the first 24 hours is pathological until proven otherwise.
AAP 2022 Key Changes from Prior Guidelines
- Lower phototherapy thresholds — particularly protective for late preterm (35–37 weeks) infants
- Universal predischarge TSB or TcB screening recommended for all newborns ≥35 weeks
- Neurotoxicity risk factors now explicitly lower the treatment threshold for the same gestational age
- Emphasis on ensuring adequate breastfeeding/nutrition to prevent dehydration-associated jaundice
- G6PD testing recommended for all newborns in high-prevalence populations (including India)
Phototherapy — Mechanism and Delivery
Phototherapy works by photo-isomerizing unconjugated bilirubin in the skin and superficial capillaries into water-soluble lumirubin and Z,E-bilirubin isomers, which are excreted in urine and bile without requiring hepatic conjugation. Efficacy depends on spectral irradiance (minimum 30 µW/cm²/nm at 460–490 nm wavelength), body surface area exposed (use of a blanket underneath increases efficacy), and duration. Intensive phototherapy (multiple lights, bili-blanket) is used for rapidly rising or near-exchange bilirubin levels.
When to Consider Exchange Transfusion
Double-volume exchange transfusion (DVET) is the treatment of last resort for severe hyperbilirubinemia when intensive phototherapy fails to reduce bilirubin adequately, or when TSB is at or above the exchange transfusion threshold. DVET carries significant risks including infection, electrolyte imbalance, thrombocytopenia, and rarely death, and should be performed only in a NICU setting by experienced clinicians.
Frequently Asked Questions
Is jaundice in the first 24 hours always pathological?
Yes. Any visible jaundice or bilirubin elevation within the first 24 hours of life is considered pathological until a cause is identified. The most common cause is ABO or Rh isoimmune haemolysis. These babies need urgent evaluation, blood group and Coombs testing, and often early phototherapy.
Can a breastfed baby have higher bilirubin?
Yes — two distinct conditions are recognized. "Breastfeeding jaundice" occurs in the first week due to inadequate milk intake and dehydration, which concentrates bilirubin. "Breast milk jaundice" is a separate, later-onset condition (week 2–3) caused by a substance in mature breast milk that inhibits bilirubin conjugation. Both are benign but should be distinguished from pathological causes.
What is TcB and when is TSB needed?
Transcutaneous bilirubin (TcB) is a non-invasive screening tool measured with a bilirubinometer on the forehead or sternum. It correlates well with TSB for routine screening but is less reliable in infants with dark skin, pre-treatment with phototherapy, or very high bilirubin levels. When TcB is above the phototherapy threshold zone or in any high-risk infant, a confirmatory total serum bilirubin (TSB) blood test should be obtained.
How long does phototherapy take to work?
With standard phototherapy, TSB typically declines by 1–2 mg/dL in the first 4–6 hours, and by 30–40% over 24 hours. A TSB recheck is typically done 4–6 hours after starting phototherapy in near-threshold cases, and 12–24 hours in less urgent cases. Phototherapy is discontinued when TSB falls at least 2 mg/dL below the treatment threshold and the infant is feeding well.